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Expression of activatedmutants of c-Src in epithelial cells can
induce tumorigenicity. In addition to such oncogenic transfor-
mation, the cells undergo a dramatic morphological transfor-
mation: cell-cell contacts are disrupted, spreading on extracel-
lular matrix proteins is suppressed, actin stress fibers and focal
contacts are lost, and podosomes are formed. We have previ-
ously shown that integrin v3 strongly supports Src-medi-
ated oncogenic transformation through an interaction at the
3 cytoplasmic tail. Our current findings demonstrate that
this interaction does not affect Src-mediated morphological
alterations, thus separating oncogenic from morphological
transformation. Moreover, 1 and 3 integrins differently
affect the various aspects of Src-induced morphological
transformation. High levels of 3, but not 1, integrins can
prevent Src-induced cell rounding although stress fiber dis-
assembly and podosome formation still occur. Studies using
chimeric integrin subunits demonstrate that this protection
requires the 3 extracellular domain. Finally, like tumor for-
mation, podosome assembly occurs independent of 3 phos-
phorylation. Instead, phosphorylation of 1 is required to
suppress Rho-mediated contractility in order to assemble
podosomes. Thus, integrins regulate Src-mediated oncogenic
transformation and various aspects of morphological trans-
formation through dissociable pathways.
The ubiquitously expressed Src family kinase c-Src is
involved in pro-survival and mitogenic signaling cascades (1).
Activated mutants of Src, including the oncogenic product of
Rous sarcoma virus (v-Src), can induce anchorage- and growth
factor-independent growth of cell lines in vitro and tumor for-
mation in vivo (2–4). c-Src has been found to play a critical role
in the development of cancer in mice (5, 6), and expression
and/or activity of c-Src is frequently increased in human mela-
noma and carcinomas of the breast, colon, and other epithelia
(4, 7, 8). Activation of Ras, phosphatidylinositol 3-kinase, and
Stat3 has been implicated in Src-mediated oncogenic transfor-
mation (3).
In addition to its role inmitogenic signaling, c-Src is a critical
regulator of both cadherin- and integrin-mediated adhesion
structures (9, 10). While low levels of c-Src kinase activity or
kinase-independent functions of c-Src can support the forma-
tion of cell-cell or cell-matrix adhesions (11–13), c-Src kinase
activation typically stimulates the disassembly of these struc-
tures (14, 15). Indeed, expression of activated mutants of Src in
epithelial cells induces scattering, loss of cytoskeletal contrac-
tility, weak adhesion, cell rounding, and the formation of highly
dynamic cell-matrix adhesions termed podosomes that are
considered to be hotspots for invasion and matrix remodeling
(9, 16–18).
It is not clear to what extent the signaling pathways activated
by Src that are involved in oncogenic transformation overlap
with those involved in the morphological transformation.
Moreover, the different aspects of Src-induced morphological
transformation may be connected (e.g. they may all be
explained to some extent by loss of actomyosin contractility) or
may involve activation of distinct signaling processes (e.g. sep-
arable alterations at cell-cell junctions, within the cytoskeletal
contractility machinery, and at cell-matrix adhesions). In cell-
matrix adhesions, integrins can serve as direct phosphorylation
substrates of v-Src, which suppresses integrin function and
weakens cell-matrix adhesion. Phosphorylation of the cyto-
plasmic domain of 1 integrins was shown to be critical for
v-Src-mediated morphological transformation (19). Others
have found that v-Src phosphorylates and reduces the affin-
ity of 3, but not of 1, integrins, and instead an indirect
mechanism that disrupts 1 integrin-mediated cell adhesion
was proposed (20, 21).
To clarify howdifferent integrins regulate the various aspects
of Src-mediated morphological transformation and how this
relates to oncogenic transformation, we have expressed a c-Src
mutant that is constitutively in an open, primed conformation
(c-Src[Y530F], here referred to as SrcYF) in the context of wild
type, chimeric, and mutant 1 and 3 integrin subunits in two
independent 1-deficient cell lines. While overexpression of
v3 augments SrcYF-mediated tumor growth through an
interaction at the 3 cytoplasmic tail (22), the v3 extracellu-
lar domain protects against SrcYF-induced cell rounding.More-
over, like tumor formation SrcYF-induced podosome assembly
occurs independent of 3 phosphorylation. Instead, phospho-
rylation of 1 is required to suppress Rho-mediated contractil-
ity in order to assemble podosomes. Thus, integrins uncouple
SrcYF-mediated oncogenic transformation and various aspects
of morphological transformation.
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EXPERIMENTAL PROCEDURES
Cell Lines, Plasmids, Antibodies, and Other Materials—The
1-deficient GE11 and GD25 cells were previously described
(23). Cells were cultured in Dulbecco’s modified Eagle’s
medium supplemented with 10% fetal calf serum and antibiot-
ics. To ensure identical expression of SrcYF in all cell lines, we
first generatedGESrcYF andGDSrcYF single cell clones and sub-
sequently expressed the wild type, mutant, and chimeric inte-
grin subunits using retroviral transduction and bulk sorting
(22). Retroviral expression constructs for 1, 3, 1ex3in,
3ex1in, 3Y747A, and 3Y759A were described (22, 24) and the
LZRS-zeo-1Y783F,Y795F cDNA was provided by Dr. Ed Roos,
Netherlands Cancer Institute, Amsterdam, The Netherlands.
To compare wild type 3 and 3YYFF, pcDNA3-3 (25) and
pRC/RSV-3Y747F,Y759F (provided byDr. Scott Blystone, SUNY
UpstateMedicalUniversity, Syracuse,NY), plasmidswere tran-
siently transfected in parallel using Effectene (Qiagen) and ana-
lyzed by immunofluorescence. The following integrin-specific
antibodies have been used: anti-human 1 clones TS2/16, 18
(BD Transduction Laboratories) and K20 (Biomeda), anti-hu-
man 3 SSA6 (provided by Dr. Sanford Shattil, University of
California, San Diego, CA), 23C6 (provided by Dr. Michael
Horton, University College London, UK), C20 and N20 (Santa
Cruz Biotechnology), anti-murine 1 and 5 (clones MB1.2
and BMA5, respectively; provided by Dr. Bosco Chan, Robarts
Research Institute, London, Canada). Other antibodies were
anti-paxillin clone 349 (BD Transduction Laboratories), anti-
RhoA clone 26C4 (Santa Cruz Biotechnology), anti-vimentin
clone K36 (provided by Dr. Frans Ramaekers, University of
Maastricht, The Netherlands), polyclonal anti-Myc (A-14;
SantaCruzBiotechnology), anti-phospho tyrosine (pY99; Santa
Cruz Biotechnology), and anti-tubulin clone B-5-1-2 (Sigma).
Src-selective inhibitor PP2 and the inactive PP3 analogue were
purchased fromCalbiochem. Human plasma fibronectin (FN)2
was prepared as described previously (24). Fluorescein isothio-
cyanate (FITC; Sigma) was conjugated to human plasma FN
using borate buffer (Na2B4O7, pH 9.3, 40mMNaCl) to generate
FITC-FN.
Short Term Adhesion Assays—Adhesion assays were per-
formed in 96-well tissue culture plates that were coated with 5
g/ml FN in PBS overnight at 4 °C, blocked with 2% heat-de-
natured bovine serum albumin for 2 h at 37 °C, and washed
once with PBS. Cells were trypsinized, collected in culture
medium, washed once with PBS, resuspended in Dulbecco’s
modified Eagle’s medium/0.5% bovine serum albumin, and
added to the plate at 2 104 cells/well. After 15 min of incuba-
tion at 37 °C, unattached cells were removed by rinsing the
wells with PBS; the remaining attached cells were lysed and
stained overnight at 37 °C in 3.75 mM p-nitrophenyl N-acetyl-
-D-glucosamide/0.05 M sodium citrate/0.25% Triton X-100.
Stopbuffer (50 mM glycine, pH 10.4, 5 mM EDTA) was added,
and the A405 was determined in triplicate wells and related to
the A405 measured in wells in which all 2  104 cells were
stained to calculate the percentage of adhered cells.
Immunofluorescence and Flow Cytometry—For immunoflu-
orescence, cells were fixed in 4% formaldehyde, permeabilized
in 0.4% Triton X-100, blocked with 2% bovine serum albumin,
and incubated with anti-paxillin antibody or anti-human 3
(23C6), followed by Alexa-488-conjugated secondary antibody,
rhodamine-phalloidin or TOPRO-3 staining (Molecular
Probes). Preparationsweremounted in PolyAquamount (Poly-
sciences, Inc.) and analyzed using a Bio-Rad Radiance 2100
confocal system. Images were obtained using a40 or60 oil
objective and imported in Adobe Photoshop. For flow cytom-
etry and cell sorting, cells were trypsinized, collected in culture
medium, washed with PBS, and incubated with primary anti-
bodies in PBS containing 2% serum for 1 h at 4 °C. Cells were
then washed in PBS, incubated with phycoerythrin- or allophy-
cocyanin-conjugated secondary antibodies for 1 h at 4 °C,
washed in PBS, and analyzed on a FACSCalibur or sorted on a
FACStar plus (BD Biosciences).
Rho Activity Assays—Cells were plated overnight to subcon-
fluency before lysis in Nonidet P-40 lysis buffer (0.5% Nonidet
P-40, 50mMTris-HCl, pH 7.4, 150mMNaCl, 5 mMMgCl2, 10%
glycerol, supplemented with a protease inhibitor mix (Sigma-
Aldrich)), and lysates were clarified by centrifugation at 14,000
rpm for 20 min at 4 °C. A 1% aliquot was removed for determi-
nation of total quantities of RhoA. Clarified lysates were then
incubated for 45 min at 4 °C with a glutathione S-transferase
fusion protein of the Rho-binding domain of the Rho effector
protein Rhotekin. Complexes were bound to glutathione-con-
jugated beads and washed three times in Nonidet P-40 lysis
buffer. The samples were analyzed by SDS-PAGE andWestern
blotting.
FNMatrix Assembly Assays—To visualize FNmatrix assem-
bly, cells were plated on FN-coated coverslips for 4 h and sub-
sequently incubated for an additional 20 h in medium contain-
ing 10% FN-depleted serum supplemented with 10 g/ml
biotinylated FN. Cells were fixed in 4% formaldehyde, blocked
with 2% bovine serum albumin, and stained with streptavidin-
Texas Red. Subsequently, coverslips were permeabilized in
0.4% Triton X-100 and stained with TOPRO-3. For biochemi-
cal analysis of FN matrix assembly cells were labeled with bio-
tinylated FN as described above and lysed in DOC buffer (1%
sodium deoxycholate, 20 mM Tris-HCl, pH 8.5, 2 mM N-ethyl-
maleimide, 2mM iodoacetic acid, 2mM EDTA, and 2mM phen-
ylmethylsulfonyl fluoride). Lysates were passed through a
23-gauge needle, and deoxycholate-insoluble material was
collected by centrifugation at 14,000 rpm for 20 min at 4 °C.
The pellet was washed once with DOC buffer, resolved in
reduced sample buffer, and analyzed by SDS-PAGE and
Western blotting.
Integrin Immunoprecipitations—Prior to immunoprecipita-
tion some cells were stimulated with 3 mM H2O2 and 1 mM
sodium orthovanadate for 20 min to maximize phosphoryla-
tion. Cells were lysed for 15 min at 4 °C in lysis buffer (1% Non-
idet P-40, 50mMTris-HCl, pH 7.4, 150mMNaCl, 1mM sodium
vanadate, 0.5 mM sodium fluoride, and protease inhibitor mix-
ture (Sigma-Aldrich)). Lysates were clarified by centrifugation
at 14,000 rpm for 15 min at 4 °C and precleared with protein
A-Sepharose (Amersham Biosciences) for 2 h at 4 °C. Proteins
were immunoprecipitated overnight at 4 °C with antibodies to
2 The abbreviations used are: FN, fibronectin; FITC, fluorescein isothiocya-
nate; PBS, phosphate-buffered saline.
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1 (K20) or 3 (SSA6) coupled to protein A-Sepharose. The
beads were resolved in reduced sample buffer and analyzed by
SDS-PAGE and Western blotting.
RESULTS
Morphological Transformation by SrcYF Does Not Require 1
Integrins—Srcactivationcausesadramaticchange incellularmor-
phology by interfering with adhesion and cytoskeletal organiza-
tion, processes in which integrin signaling plays a critical role. To
investigate the role of1 integrins in Src-mediatedmorphological
transformation, we expressed SrcYF in two independent 1-defi-
cient cell lines. As described for Src activation in other cell types
(9, 16), expression of SrcYF in GE11 and GD25 cells caused
disruption of cell-cell contacts and cell scattering (Fig. 1A).
Expression of SrcYF also caused a dramatic reorganization of
the actin cytoskeleton: F-actin bundles and ruffles disap-
peared and, instead, actin clusters were formed that resem-
ble podosomes (Fig. 1B). Initial adhesion (e.g. 15 min) of
GE11 and GD25 cells to FN is weak (Fig. 2A), but at later time
points (1 h) they do fully adhere and spread (Fig. 2B). Expres-
sion of SrcYF interfered with this spreading, causing a
rounded or fusiform phenotype, which was maintained after
overnight culture (Figs. 1B and 2B). These experiments show
that all aspects of SrcYF-induced morphological transforma-
tion can occur in 1 null cells, arguing against a requirement
for 1 integrins per se.
Different Aspects of SrcYF-mediated Morphological Trans-
formation Can Be Separated; Distinct Roles for 1 and 3
Integrins—Expression of 1 in GE11 and GD25 cells led to a
strong increase in cell adhesion to FN (70% of the cells
attached at 15 min after plating) that was suppressed by SrcYF
(Fig. 2A). At later times (e.g. 1 h after plating), GE1 and GD1
cells had all adhered regardless of the absence or presence of
SrcYF, but in the presence of SrcYF cells remained rounded (Fig.
2B). In complete contrast, overexpression of 3 in the 1 null
cells led to a similar increase in adhesion and spreading to FN as
expression of 1 but this was only minimally affected by SrcYF
FIGURE 1. Morphological transformation by SrcYF does not require 1
integrins. A, phase-contrast images of integrin 1-deficient GE11 and GD25
cells with or without stable expression of SrcYF. Cells were cultured on an
FN-coated coverslip for 2 days to allow cell-cell contact formation. B, immun-
ofluorescent images ofGE11 andGD25 cells thatwereplatedovernight on an
FN-coated coverslip and subsequently stainedwithphalloidin to visualize the
F-actin cytoskeleton. Podosomes indicated by white arrows are shown
enlarged in the insets. Scale bar, 25 or 5 m (inset).
FIGURE2.3 integrinprotectsagainstSrcYF-induced lossofadhesionand
spreading. A, graphs indicate the average percentage  S.D. of adherent
cells 15 min after plating from two independent FN adhesion assays per-
formed in triplicate wells. Asterisks indicate significant difference between
average values (t-test, p 0.01). Expression of various constructs is shown at
the bottom of the graph. B, phase contrast images of GE11 and GD25 cells
expressing indicated constructs that were plated on an FN-coated surface for
1 h.
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(Fig. 2, A and B). Notably, after overnight culture SrcYF1-ex-
pressing cells retained a fusiform or even rounded shape
whereas SrcYF3-expressing cells remained well spread (Fig.
4A). This indicates that SrcYF did not simply delay 1-integrin-
mediated spreading but caused a permanent morphological
alteration that was not seen in the context of v3. Finally,
expression of1 inGESrcYF3 cells did not alter thewell spread
morphology of these cells, indicating that v3-mediated pro-
tection against SrcYF-induced cell rounding was dominant
(supplemental Fig. S1, A and B).
We have reported that expression of 1 integrins in GE11
and GD25 cells stimulates Rho-mediated cytoskeletal contrac-
tility and FNmatrix assembly, whereas overexpression of 3 in
1 null cells is unable to do so (24). We wondered whether
higher levels of Rho-mediated cytoskeletal contractility could
also explain the inhibition of cell spreading in the SrcYF-trans-
formed cells expressing 1 integrins. However, in the presence
of SrcYF, RhoA-GTP levels in 1-expressing cells were dramat-
ically suppressed to levels that were comparable with those in
cells lacking 1 (Fig. 3A). Moreover, FN matrix assembly, a
process that requires Rho-mediated contractility, was strongly
reduced upon introduction of SrcYF (Fig. 3, B and C).
Subsequently, we investigated whether 1 and 3 integrins
affected SrcYF-mediated podosome assembly. Despite the
markedly different sensitivities of 1- and 3-mediated adhe-
sion and spreading to suppression by SrcYF (Fig. 2), loss of F-ac-
tin stress fibers and conversion of focal adhesions into podo-
somes was seen in each case (Fig. 4A). Podosomes of SrcYF1
cells often consisted of F-actin dots that were tightly sealed
FIGURE 3. SrcYF suppresses RhoA activation and FN matrix assembly.
A,Westernblot analysis of RhoAactivity assayon lysatesofGE11cells express-
ing indicated constructs. B, Western blot analysis of assembled FN biotin and
vimentin (loading control) in deoxycholate-insoluble lysates of GE11 cells
expressing the indicated constructs. C, images of assembled FN biotin on
GE11 cells expressing the indicated constructs. TOPRO staining was used to
visualize nuclei; scale bar, 25 m.
FIGURE 4. SrcYF-induced podosome formation in cells expressing
either 1 or 3 integrins. A, immunofluorescent images of GE11 and
GD25 cells expressing the indicated constructs, plated overnight on FN-
coated coverslips and stained with phalloidin. Scale bar, 25 m. Insets
show enlargements of the regions, indicated by dotted squares. Scale bars,
25 or 5 m (insets). B, immunofluorescent images of GE11 and GD25 cells
expressing indicated constructs stained with phalloidin. Before fixation,
adherent cells were treated with 10 M PP2 or PP3 (control) for 6 h in com-
plete culturemedium. Scale bar, 25m.C, graph showsaquantificationof the
percentage  S.D. of podosome-containing cells in at least five different
fields of two independent experiments as in B. Asterisks indicate significant
difference between average values (t-test, p 0.01).
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together, whereas more dispersed, individual, small F-actin
dots were present in SrcYF3 cells, which may be explained by
increased cell spreading (see Fig. 4A, insets). The podosomes
that were formed in each of the SrcYF-transformed cell types
were dependent on SrcYF kinase activity, because treatment
with the Src-selective kinase inhibitor PP2 led to their disas-
sembly (Fig. 4, B and C).
Taken together, these results demonstrate that (i) high levels
of 3, but not 1, integrins protect SrcYF-transformed cells
from rounding up and (ii) two typical aspects of SrcYF-induced
morphological transformation, cell rounding and podosome
formation, are distinct processes and are differently affected by
the integrin expression profile.
SrcYF-induced Podosomes Are Proteolytically Active Irrespec-
tive of the Integrin Type—Formation of podosomes is a mor-
phological hallmark of Src transformation, and these adhesions
are thought to be hotspots for invasion and proteolytic remod-
eling of the extracellular matrix (17, 18). We next tested
whether the integrin expression profile affected the proteolytic
activity of these podosomes. No matrix degradation was
observed to be associated with focal contacts in GE1 and
GE3 cells in the absence of SrcYF when plated on immobilized
FITC-labeled FN (Fig. 5). By contrast, podosomes formed in
GESrcYF1 and GESrcYF3 cells were both able to degrade
FITC-FN. Proteolytic activity was often evident at sites outside
cell borders, indicating that cells had moved along these sites
(Fig. 5, arrowheads). Thus, podosomes in SrcYF-transformed
cells are proteolytically active, irrespective of the integrin
composition.
Oncogenic and Morphological
Transformations Are Separated by
Distinct Integrin Domains—We
have previously shown that v3
strongly supports SrcYF-mediated
tumorigenesis through an interac-
tion between the 3 cytoplasmic
domain and the Src homology 3
domain (22).We examined whether
this was related to the capacity of
v3 to protect cells against SrcYF-
induced rounding (Figs. 2 and 4).
Therefore, we expressed a chimeric
1ex3in subunit, consisting of a 1
extracellular and transmembrane
region fused to the cytoplasmic tail
of 3, or an inverse 3ex1in integrin
in GESrcYF cells (supplemental Fig.
S1C). Using these chimeric inte-
grins we demonstrated that the 3
cytoplasmic domain was required
and sufficient for the stimulation of
SrcYF-mediated tumor growth (Fig.
6C, left graph, and Ref. 22). In com-
plete contrast, v3-mediated pro-
tection against SrcYF-induced cell
rounding required the 3 extracel-
lular domain: 3ex1in failed to sup-
port tumor growth but effectively rescued short term cell adhe-
sion and subsequent spreading, whereas the opposite was the
case for a 1ex3in chimera (Fig. 6, A and C). Like adhesion and
spreading, the appearance of podosomes was unaffected by the
integrin cytoplasmic tail swap: podosomes in the presence of
1ex3in resembled those of 1-expressing cells and were often
sealed together, whereas podosomes of3ex1in-expressing cells
were comparable with those expressing 3, consisting mainly
of dispersed small F-actin dots (Fig. 6B). These results demon-
strate that (i) high levels ofv3 support SrcYF-mediated tumor
formation and protect against SrcYF-induced loss of adhesion
and spreading through distinct mechanisms and (ii) SrcYF-me-
diated oncogenic and morphological transformation can be
separated.
Podosome Formation Requires SrcYF-mediated Phosphoryla-
tion of the 1 Cytoplasmic Tail to Suppress Cytoskeletal
Contractility—Integrin cytoplasmic tails serve as direct phos-
phorylation substrates of v-Src, which impairs their adhesive
function (19, 21). Analysis of immunoprecipitated integrin 
subunits demonstrated that 1 and 3 can both be tyrosine-
phosphorylated by SrcYF (Fig. 7A), although phosphorylation
was very low compared with maximal levels reached with per-
vanadate (Fig. 7B). Using single tyrosine point mutants we have
found that phosphorylation of either of the two tyrosines in the
3 cytoplasmic tail is not required for v3-mediated support
of tumor growth (22). We observed that these mutations also
did not affect morphological transformation by SrcYF (data not
shown). Moreover, expression of a non-phosphorylatable
3Y747F,Y759F (3YYFF) subunit did not change SrcYF-mediated
morphological transformation when compared with wild type
FIGURE 5. SrcYF-induced podosomes are proteolytically active irrespective of the integrin type.
A, immunofluorescent images of indicated GE11 cells that were plated overnight on coverslips coated
with FITC-labeled FN and stained for paxillin (red). Arrows indicate spots where degradation of FITC-FN
occurred.Dotted squares indicate regions that are zoomed in and depicted in the right panel. Scale bars, 25
or 10 m (Zoom).
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3: actin stress fibers were absent and podosomes were formed
in the presence of SrcYF and 3YYFF (Fig. 7C). By contrast, in
cells expressing 1, integrin phosphorylation was crucial for
SrcYF-mediated morphological transformation. When a non-
phosphorylatable1Y783F,Y795F (1YYFF) subunit was expressed
in GESrcYF and GDSrcYF cells (supplemental Fig. S1, D and E),
SrcYF-induced podosome formation was completely abolished
(Fig. 7, D–F). Instead of podosomes that were formed in
SrcYF1 cells, F-actin stress fibers and focal contacts were
restored in SrcYF1YYFF cells and eventually these cells became
considerably more spread. These results indicate that phos-
phorylation of 1, but not 3, cytoplasmic tails is important
for SrcYF-mediated morphological transformation. Most
likely, phosphorylation is required to suppress Rho-medi-
ated cytoskeletal contractility that is promoted by 1, but
not by 3, integrins and would interfere with podosome for-
mation (Fig. 3).
DISCUSSION
In summary (see Fig. 8), we show that (i) Src-mediated onco-
genic and morphological transformations are distinct process-
es; (ii) podosome formation and cell rounding are independent
aspects of Src-mediated morphological transformation (e.g. all
cells expressing high levels of integrin subunits containing 3
extracellular domain contain podosomes but remain well
spread); (iii) v3 supports SrcYF-mediated tumor formation
and protects against SrcYF-induced loss of adhesion and
spreading through distinctmechanisms (e.g. experiments using
1ex3in and 3ex1in chimeras indicate that the 3 cytoplasmic
domain supports Src-mediated tumor growth whereas the 3
extracellular domain protects against Src-induced cell round-
ing); and (iv) Src-induced podosome assembly in the presence
of 1 requires phosphorylation of the integrin cytoplasmic
domain to reduce cytoskeletal contractility (e.g. 1YYFF). In the
absence of 1 integrins, 3 does not promote Rho-mediated
cytoskeletal contractility (24) and podosomes can be formed
without Src-mediated phosphorylation of integrin tails (e.g.
3YYFF).
Disruption of cytoskeletal contractility is one of the key
events during Src-induced morphological transformation
that enables reorganization of the actin cytoskeleton in order
to assemble podosomes. Relaxation of the actin cytoskeleton
requires inactivation of RhoA, and indeed expression of con-
stitutively activated RhoA suppresses loss of stress fibers and
podosome formation induced by v-Src (26). On the other
hand, complete inhibition of RhoA also perturbs podosomes,
indicating that local RhoA activity might still be required
(27). We find that SrcYF inhibits the ability of 1 integrins to
support RhoA-mediated contractility. The kinase activity of
SrcYF is required for podosome formation in SrcYF1- and
SrcYF3-expressing cells, and SrcYF phosphorylates 1 and
3 cytoplasmic domains. However, phosphorylation of 1,
but not 3, is important for SrcYF-mediated morphological
transformation. In line with a previous report (28), mutation
of the tyrosines in the 1 cytoplasmic tail restored focal
adhesions and cell spreading. Our findings suggest that this
is due to restored cytoskeletal contractility that prevents the
transformation from focal contacts to podosomes in the
presence of SrcYF. Indeed, overexpression of v3 fails to
promote Rho-mediated cytoskeletal contractility in 1-null
cells (24), explaining why corresponding mutations in the 3
subunit do not affect Src-mediated morphological transfor-
mation. Notably, in osteosarcoma cells phosphorylation of
3 by v-Src reduces the binding strength of v3 to FN (21).
In our studies, v3-mediated adhesion to FN was not
affected by the expression of SrcYF, which may be related to
differences between v-Src (which contains multiple addi-
tional mutations) and SrcYF (which may closely resemble
c-Src in human cancer cells where its interaction with over-
expressed receptor tyrosine kinases or mutations in the C
terminus can lead to enhanced priming) or to the moderate
SrcYF expression and integrin phosphorylation levels that we
reach in GE11 and GD25 cells. Nevertheless, these levels are
sufficient to cause all the aspects of morphological transfor-
mation and lead to rounding of 1-expressing cells.
FIGURE 6. Oncogenic and morphological transformations are separated
by distinct integrin domains. A, phase contrast images of GE11 cells
expressing indicated constructs that were plated on an FN-coated surface for
1 h to visualize spreading. B, immunofluorescent images of GE11 cells
expressing indicated constructs that were plated overnight on FN-coated
coverslips and stained with phalloidin. Scale bar, 25 or 5 m (inset). C, left
graph illustrates average tumor volume S.D. from the indicated number of
tumors of at least two independent experiments at 20 days post-subcutane-
ous injection of cells expressing the indicated constructs. Right graph shows
average percentage S.D. of adherent cells 15 min after plating from three
independent FN adhesion assays performed in triplicate wells. Please note
that the percentage of adhesion of GESrcYF1 and GESrcYF3 cells was
already presented in Fig. 2A and is shown here for direct comparison with
cells expressing chimeric integrins. Asterisks indicate significant difference
between average values (t-test, p 0.01).
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Our study dissociates SrcYF-mediated oncogenic from mor-
phological transformation and shows that different aspects of
morphological transformation (e.g. podosome formation and
cell rounding) involve separable, independent pathways. These
findings are corroborated by studies in which mitogenic activ-
ity, morphological alterations, and the anchorage independ-
ence of cells expressingmutants of v-Src were compared. It was
shown that the amino-terminal domain of v-Src is important
for determining cell morphology, whereas the kinase domain is
essential for all three parameters (29). Also, when expressed at
FIGURE 7. Effect of phosphorylation of1 and3 integrins by SrcYF. A, Western blot analysis of tyrosine-phosphorylated or total amounts of immunopre-
cipitated 1 (left) or 3 (right) integrins from GE11 cells expressing the indicated constructs. B, Western blot analysis of tyrosine-phosphorylated or total
amounts of immunoprecipitated 1 (left) or 3 (right) integrins from GE11 cells expressing the indicated constructs. Prior to lysis, cells were left untreated or
stimulated with pervanadate for 15 min. C, immunofluorescent images of GESrcYF cells transiently transfected with human 3 or 3YYFF cDNAs. Cells were
stained for human 3 integrin (green) and phalloidin (red). Arrows indicate transfected cells. D, immunofluorescent images of GE11 and GD25 cells stably
expressing the indicated1 constructs stainedwith phalloidin (red) and paxillin (green) at different time points of spreading on FN. E, highermagnifications of
the 1-h and overnight time points ofD are depicted. Scale bar, 25m. F, graph shows a quantification of the percentage S.D. of podosome-containing cells
after overnight spreading in at least five different fields of two independent experiments as in D. Asterisks indicate significant difference between average
values (t-test, p 0.01).
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very low levels in Madin-Darby canine kidney cells, v-Src elic-
ited disruption of zonula adherences, which was dissociable
from oncogenic transformation, as determined by anchorage-
independent growth capacity and proliferation (30). Attempts
to transform c-Myc-deficient fibroblasts with v-Src resulted in
morphological transformation but failed to induce DNA syn-
thesis and proliferation (31). All together, these studies show
that signaling downstream of Src can occur through multiple
independent pathways. Our current work indicates that the
integrin expression profile differentially modulates all these
aspects of Src transformation.
In human cancer increased expression and activity of c-Src
contributes to tumor development through stimulation of
mitogenic signaling pathways in which c-Src normally plays a
regulatory role (10, 32). In addition, reorganization of the actin
cytoskeleton, cell-cell, and cell-matrix adhesions upon Src acti-
vation may contribute to tumor invasion and metastasis (4, 9).
Interestingly, changes in the expression profile of integrins
often occur with tumor formation and during later steps of
tumor progression. Increased expression levels of v3 are
associated with growth and progression of various cancers (33).
For example, high levels of v3 promote the conversion from
radial to vertical growth phase in human melanoma (34, 35), a
cancer type in which c-Src activity is frequently increased (4).
Our findings suggest that such changes in integrin expression
can have a dramatic impact on Src-mediated effects on growth
and/or invasion of tumors. Cooperation between integrinv3
and c-Srcmay be important for tumor growth, whereas shifts in
the relative expression of 1 and 3 integrins might be impor-
tant to control tumor cell adhesion and spreading during can-
cer progression.
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